177 related articles for article (PubMed ID: 20558841)
21. Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.
Zoppoli G; Cea M; Soncini D; Fruscione F; Rudner J; Moran E; Caffa I; Bedognetti D; Motta G; Ghio R; Ferrando F; Ballestrero A; Parodi S; Belka C; Patrone F; Bruzzone S; Nencioni A
Exp Hematol; 2010 Nov; 38(11):979-88. PubMed ID: 20696207
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.
Nakashima H; Uto Y; Nakata E; Nagasawa H; Ikkyu K; Hiraoka N; Nakashima K; Sasaki Y; Sugimoto H; Shiro Y; Hashimoto T; Okamoto Y; Asakawa Y; Hori H
Bioorg Med Chem; 2008 Sep; 16(18):8661-9. PubMed ID: 18715787
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of increased indoleamine 2,3-dioxygenase activity attenuates Toxoplasma gondii replication in the lung during acute infection.
Murakami Y; Hoshi M; Hara A; Takemura M; Arioka Y; Yamamoto Y; Matsunami H; Funato T; Seishima M; Saito K
Cytokine; 2012 Aug; 59(2):245-51. PubMed ID: 22609210
[TBL] [Abstract][Full Text] [Related]
24. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
[TBL] [Abstract][Full Text] [Related]
25. Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity.
Gerner RR; Macheiner S; Reider S; Siegmund K; Grabherr F; Mayr L; Texler B; Moser P; Effenberger M; Schwaighofer H; Moschen AR; Kircher B; Oberacher H; Zeiser R; Tilg H; Nachbaur D
Leukemia; 2020 Jul; 34(7):1885-1897. PubMed ID: 31974433
[TBL] [Abstract][Full Text] [Related]
26. Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells.
El Kholy NM; Sallam MM; Ahmed MB; Sallam RM; Asfour IA; Hammouda JA; Habib HZ; Abu-Zahra F
Med Oncol; 2011 Mar; 28(1):270-8. PubMed ID: 20300979
[TBL] [Abstract][Full Text] [Related]
27. Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan.
Zeng J; Cai S; Yi Y; He Y; Wang Z; Jiang G; Li X; Du J
Cancer Res; 2009 May; 69(9):3963-70. PubMed ID: 19383920
[TBL] [Abstract][Full Text] [Related]
28. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.
Inaba T; Ino K; Kajiyama H; Yamamoto E; Shibata K; Nawa A; Nagasaka T; Akimoto H; Takikawa O; Kikkawa F
Gynecol Oncol; 2009 Nov; 115(2):185-92. PubMed ID: 19665763
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.
Bi TQ; Che XM; Liao XH; Zhang DJ; Long HL; Li HJ; Zhao W
Oncol Rep; 2011 Nov; 26(5):1251-7. PubMed ID: 21743967
[TBL] [Abstract][Full Text] [Related]
30. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
Barraud M; Garnier J; Loncle C; Gayet O; Lequeue C; Vasseur S; Bian B; Duconseil P; Gilabert M; Bigonnet M; Maignan A; Moutardier V; Garcia S; Turrini O; Delpero JR; Giovannini M; Grandval P; Gasmi M; Ouaissi M; Secq V; Poizat F; Guibert N; Iovanna J; Dusetti N
Oncotarget; 2016 Aug; 7(33):53783-53796. PubMed ID: 27462772
[TBL] [Abstract][Full Text] [Related]
31. NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
Zhang XQ; Lu JT; Jiang WX; Lu YB; Wu M; Wei EQ; Zhang WP; Tang C
Neuroscience; 2015 Apr; 291():230-40. PubMed ID: 25684751
[TBL] [Abstract][Full Text] [Related]
32. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.
Metz R; Duhadaway JB; Kamasani U; Laury-Kleintop L; Muller AJ; Prendergast GC
Cancer Res; 2007 Aug; 67(15):7082-7. PubMed ID: 17671174
[TBL] [Abstract][Full Text] [Related]
33. Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells.
Travelli C; Drago V; Maldi E; Kaludercic N; Galli U; Boldorini R; Di Lisa F; Tron GC; Canonico PL; Genazzani AA
J Pharmacol Exp Ther; 2011 Sep; 338(3):829-40. PubMed ID: 21685314
[TBL] [Abstract][Full Text] [Related]
34. The Combined Use of Melatonin and an Indoleamine 2,3-Dioxygenase-1 Inhibitor Enhances Vaccine-Induced Protective Cellular Immunity to HPV16-Associated Tumors.
Moreno ACR; Porchia BFMM; Pagni RL; Souza PDC; Pegoraro R; Rodrigues KB; Barros TB; Aps LRMM; de Araújo EF; Calich VLG; Ferreira LCS
Front Immunol; 2018; 9():1914. PubMed ID: 30186285
[TBL] [Abstract][Full Text] [Related]
35. An albumin-bound drug conjugate of paclitaxel and indoleamine-2,3-dioxygenase inhibitor for enhanced cancer chemo-immunotherapy.
Hu Z; Zheng B; Xu J; Gao S; Lu W
Nanotechnology; 2020 May; 31(29):295101. PubMed ID: 32203949
[TBL] [Abstract][Full Text] [Related]
36. Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer.
Salvadori ML; da Cunha Bianchi PK; Gebrim LH; Silva RS; Kfoury JR
Med Oncol; 2015 Nov; 32(11):248. PubMed ID: 26442514
[TBL] [Abstract][Full Text] [Related]
37. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO.
Zhang A; Zheng Y; Que Z; Zhang L; Lin S; Le V; Liu J; Tian J
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1883-90. PubMed ID: 24980548
[TBL] [Abstract][Full Text] [Related]
38. Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma.
Gasparri AM; Jachetti E; Colombo B; Sacchi A; Curnis F; Rizzardi GP; Traversari C; Bellone M; Corti A
Mol Cancer Ther; 2008 Dec; 7(12):3859-66. PubMed ID: 19074858
[TBL] [Abstract][Full Text] [Related]
39. IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells.
Maleki Vareki S; Chen D; Di Cresce C; Ferguson PJ; Figueredo R; Pampillo M; Rytelewski M; Vincent M; Min W; Zheng X; Koropatnick J
PLoS One; 2015; 10(11):e0143435. PubMed ID: 26579709
[TBL] [Abstract][Full Text] [Related]
40. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
